June 2016
 Pour la dernière newsletter avant l'été, nous sommes heureux d'annoncer le démarrage de deux projets collaboratifs importants dans lesquels nous sommes fortement impliqués : CHOPIN et Innovcell3D. C'est une vraie reconnaissance des compétences scientifiques de notre entreprise.
Nous vous proposons également de découvrir notre nouveau service sur le test des comets automatisé en plaque 96-puits et un portrait de Pierre-Jean Ferron, notre nouveau directeur d'étude.
Enfin, si vous voulez emporter en vacances quelque chose à lire, pourquoi ne pas jeter un œil au dernier rapport de Kalorama Information sur l'externalisation de la recherche de médicaments ?
Nous vous souhaitons un bon été ! Rendez-vous en septembre.
 In this last newsletter before the summer, we are pleased to announce the start of two major collaborative projects in which we are heavily involved : CHOPIN and Innovcell3D. It is a true recognition of our scientific skills.
We also offer you to discover our new service on the automation of "Comet assays" and a portrait of Pierre-Jean Ferron, our new study director.
Finally, if you want to take on holiday something to read, why not to consult the latest report from Kalorama Information on outsourcing of drug research?
Have a great summer! See you in September.

Project CHOPIN selected by the French ANR, and we’re in !

HCS Pharma is proud to be a part of the CHOPIN Project (CHolesterol Personalized INnovation). Selected as one of the ten most innovative health research programs by the ANR (French Research Agency), the project will receive more than €8 million euros through the second wave of the “Investissements d’Avenir” (i.e. “Investing for the future” ) program of the French government.

Genotoxicity assay development in collaboration with Galderma R&D

During ELRIGfr event in Rennes, We had the opportunity to present our work on genotoxicity assay (comet assay on TK6 & gH2AX on keratinocytes and HepG2) in collaboration with the team of in vitro of Galderma R&D.

New Posters and Services available

Automated comet assay for genotoxicity and DNA damage protection analysis : HCS Pharma has combined processes to perform an automated comet assay, from the cell and agarose handling, to comet assessment and scoring, by using automated instrumentation and a 96-well format comet slide. This fully automated process can allow us to test your compounds or active ingredients in medium throughut (96-well plates) either in genotoxicity assays or in efficacy assay as DNA damage protection assays.

New publication of HCS interest in Drug Discovery

We are always happy to read reports showing the growing interest of the research for high content screening. For those interested, you can find in this article to appear, an expert opinion on High Content Screening in the drug-discovery processes.

Innovcell3D Project in collaboration with INSERM U991

We are happy to announce that Brittany region continue to help us (article in french) and co-funds one of our R&D projects in collaboration with Dr Anne Corlu, head of team 2 and Dr Bernard Fromenty, head of team 3 of UMR991 directed by Dr Bruno Clément in Rennes.

Welcome Pierre-Jean as new HCS Pharma study director !

We are very happy to present you Pierre-Jean Ferron, who joined HCS Pharma as a study director, specialized in cellular biology and high content analysis.

Drug Discovery Market

A brand new article from Genetic Engineering and Biotechnology News leans on a report of Kalorama information to show the importance of outsourcing Drug Discovery and so on the growing potential of this market.

We were at e-health event by L’Usine Digital !

We were pleased to talk at e-health day organised in Paris by L’Usine Digital. Our intervention was focused on the importance of public/private collaboration for today innovation in biotechnology. Our CEO, Nathalie Maubon and our partner Karim SI-TAYEB, from Institut du Thorax de Nantes, explained how they work together on cardio-metabolic diseases.


Explain us your requirements and we develop your assays to best meet your needs !

Why HCS ?

To target complex diseases (as cancer and neurodegenerative diseases), more than one target are needed and screening on complex model is recommended.

View this email in your browser
Google Plus
Google Plus
Contact Us
Contact Us
Copyright © 2016 HCS Pharma, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp